Electra Therapeutics Inc. Company Profile
NASDAQ: ETRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 10:53 AM ET
Electra Therapeutics at a glance
Electra Therapeutics Inc. (NASDAQ: ETRA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in South San Francisco, CA. Electra Therapeutics is led by Dr. Quehuong Dong M.B.A., Pharm.D. and employs about 46 people. The company's shares have traded publicly since 2026.
At a market capitalization of $574.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002088082, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Electra Therapeutics do?
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- Electra Therapeutics Inc.
- Ticker
- NASDAQ: ETRA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Quehuong Dong M.B.A., Pharm.D.
- Employees
- 46
- Headquarters
- 230 E Grand Avenue, South San Francisco, CA, United States
- Phone
- (888) 743-2290
- Website
- electra-therapeutics.com
- IPO year
- 2026
- Market cap
- $574.95M
- SEC CIK
- 0002088082
Companies similar to Electra Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DBVTDBV Technologies S.A. ADR | 9.53 | -0.21% | $598.95M | vs ETRA |
| VALNValneva SE ADR | 5.74 | +0.88% | $544.29M | vs ETRA |
| RGNXREGENXBIO Inc. | 8.07 | -0.25% | $532.73M | vs ETRA |
| ALLOAllogene Therapeutics Inc. | 1.40 | 0.00% | $483.69M | vs ETRA |
| PROKProKidney Corp. Class A | 1.68 | +0.90% | $668.63M | vs ETRA |
| AUTLAutolus Therapeutics plc ADR | 1.78 | +0.56% | $473.77M | vs ETRA |
| AURAAura Biosciences Inc. | 6.55 | +0.69% | $679.27M | vs ETRA |
| PRMEPrime Medicine Inc. | 3.81 | +6.42% | $691.05M | vs ETRA |